Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

December 31, 2015

Conditions

Healthy

Interventions

DRUG

BCD-054

DRUG

Rebif

DRUG

Avonex

Trial Locations (1)

"OOO BioEk", Saint Petersburg